Hemic and Lymphatic Diseases

593 trials 238 recruiting

Filter these 593 trials by phase, country and sponsor.

Open in Search →

Clinical study in order to compare the effectiveness and safety of two different treatments in patients with newly diagnosed primary immune … Ended

2024-514147-28-00 Primary immune thrombocytopenia 5 2022-12-02
Study of the safety and efficacy of treatment venetoclax + azacitidine and donor lymphocyte infusion in patients with MDS or AML in relapse … Ended

2024-514877-23-00 Myelodysplastic syndromes or Acute Myeloid Leukemia 9 2022-11-23
A Study to Investigate Tolerability and Efficacy of Asciminib (Oral) Versus Nilotinib (Oral) in Adult Participants (≥18 Years of Age) With N… Ended

2024-510947-71-00 Chronic Myeloid Leukemia 5 2022-11-21
Extended VRD plus Early Rescue vs Isatuximab-VRD vs Isatuximab-VIberdomide-D for NDMM patients who are candidates for ASCT Ended

2024-517008-12-00 Newly-diagnosed multiple myeloma (NDMM) 5 2022-10-14
Multicenter, phase II, national and open-label study to evaluate Iberdomide-dexamethasone alone or in combination with standard MM treatment… Ended

2024-518870-15-00 Multiple Myeloma 4 2022-10-03
A Study to Evaluate How Safe Pozelimab + Cemdisiran Combination Therapy is and How Well it Works in Adult Patients with Paroxysmal Nocturnal… Ended

2023-509657-31-00 Paroxysmal nocturnal haemoglobinuria (PNH) 5 2022-08-24
Pilot phase II study of Selinexor in combination with Ifosfamide, Etoposide and Dexamethasone (SIDE) in patients with relapsed or refractory… Ended

2024-513295-18-00 Relapsed or Refractory Peripheral T-cell Lymphomas 4 2022-08-10
Study to Evaluate how effective and safe the investigationall product, Mitapivat, is when administred to Pediatric Subjects With Pyruvate Ki… Ended

2024-515024-37-00 Pyruvate Kinase Deficiency 5 2022-05-27
A Phase 2, Open-Label, Ascending Dose Study of KER-050 for the Treatment of Anemia in Patients with Very Low, Low, or Intermediate Risk Myel… Ended

2023-507469-24-00 Anemia in Patients with Very Low, Low, or Intermediate 4 2022-04-30
Study to Evaluate the Safety and Efficacy of Efgartigimod (ARGX-113) PH20 Subcutaneous in Adult Patients With Primary Immune Thrombocytopeni… Ended

2024-513147-90-00 Primary Immune Thrombocytopenia 5 2022-04-26
A study to evaluate KER-050 as a monotherapy or in combination with Ruxolitinib in Myelofibrosis. Ended

2023-507468-38-00 Myelofibrosis 4 2022-04-22
A Study to Evaluate Overall Health, Physical Activity and Joint Outcomes, in Participants with Severe or Moderate Hemophilia A without FVIII… Ended

2023-505747-40-00 Severe or Moderate Hemophilia A 6 2022-04-20
A study to Evaluate the Efficacy and Safety of Mitapivat in Subjects With Non Transfusion-Dependent Alpha- or Beta-Thalassemia (ENERGIZE) Ended

2024-512745-16-00 Non–Transfusion-Dependent Alpha- or Beta-Thalassemia 5 2022-04-13
Intravenous Immunoglobulin plus oral prednisone or high-dose dexamethasone, for adults with immune thrombocytopenia (ITP) with moderate and … Ended

2024-516403-16-00 Adult patients with immune thrombocytopenia (ITP) with 5 2022-04-07
Consolidation with ADCT-402 (loncastuximab tesirine) after a short course of immunochemotherapy: a phase II study in BTKi-treated (or BTKi i… Ended

2024-511633-35-00 Mantle cell lymphoma 4 2022-03-21
A Study to Evaluate the Safety and Pharmacokinetics of a Modified Tafasitamab IV Dosing Regimen Combined with Lenalidomide in Patients with … Ended

2023-507993-42-00 Relapsed or Refractory Diffuse Large B-Cell Lymphoma ( 9 2022-03-17
PCL-2 - PRIMARY PLASMA CELL LEUKEMIA: A PROSPECTIVE PHASE II STUDY INCORPORATING DARATUMUMAB TO CHEMOTHERAPY AND STEM CELL TRANSPLANTATION (… Ended

2024-515037-15-00 PRIMARY PLASMA CELL LEUKEMIA: A PROSPECTIVE PHASE II ST 4 2022-03-02
Study aimed at evaluating the efficacy of the combination of the two drugs, Venetoclax and Azacitidine, on the treatment of patients sufferi… Ended

2023-510432-36-00 Acute Myeloid Leukemia with NPM1 mutation 4 2022-03-01
Assessment of effectiveness and safety of luspatercept in patients suffering from lower-risk myelodysplastic syndrome. Ended

2024-515069-33-00 Patients with anemia due to IPSS-R defined very low-, l 5 2022-02-15
OASIS II - A randomized phase II trial evaluating Ibrutinib plus CD20 Ab and Ibrutinib-Venetoclax plus CD20 Ab in patients with untreated ma… Ended

2024-512634-15-00 Patients with untreated mantle cell lymphoma 9 2022-01-05
A Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Mosunetuzumab (BTCT4465A) in Combination with Polatuzumab Ved… Ended

2023-506986-74-00 B-cell non-Hodgkin lymphoma (NHL) 9 2021-12-27
VERLEN - Phase II, Open-Label Study evaluating efficacy of Lenalidomide and Tafasitamab combination associated to Rituximab in frontline Dif… Ended

2023-507286-25-00 Diffuse Large B-Cell Lymphoma 4 2021-12-23
This study is a randomized, placebo-controlled, double-blind, multicenter Phase 2/3 study of patients, age 12 to 65 years, with sickle cell … Ended

2024-511535-97-00 sickle cell disease (SCD) 10 2021-12-16
Acalabrutinib and rituximab in elderly patients with untreated mantle cell lymphoma (ALTAMIRA) Ended

2023-509864-96-00 Mantle Cell Lymphoma (MCL) 4 2021-12-07